A review conducted internally by Johnson & Johnson soon after it recalled a troubled hip implant found that the company had not adequately assessed the device's potential risks before it was used in more than 90,000 patients, court testimony on Thursday showed.
Ukubukeza olwenziwa ngaphakathi by Johnson & Johnson ngokushesha ngemuva likhumbula zikhathazeke hip nolwelwesi wathola ukuthi inkampani wayengazange ngokwanele uhlolwa izingozi yedivayisi engaba phambi lalisetshenziswa ezingaphezu kuka 90,000 iziguli.